Caris Life Sciences (Caris), one of the leading TechBio companies, recently announced that the University of New Mexico Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance (Caris POA), a global network of leading cancer centers, academic institutions, research organizations and healthcare systems focused on advancing precision oncology and biomarker-driven research.
The addition of the UNM Comprehensive Cancer Center strengthens the growing Caris POA network, which brings together institutions committed to accelerating cancer research, expanding access to comprehensive molecular profiling and advancing the development of innovative approaches to personalized cancer care. The Caris POA focuses on precision oncology patient care, research and publications, education and mentoring, and sequencing support for clinical trials.
“Welcoming the University of New Mexico Comprehensive Cancer Center to the Caris Precision Oncology Alliance reflects our continued commitment to expanding collaborative cancer research and bringing the promise of precision medicine to more patients,” said James Hamrick, MD, MPH, Chairman of the Caris Precision Oncology Alliance. “Together, we will leverage molecular science, clinical expertise and real-world evidence to generate insights that help improve outcomes for patients facing cancer.”
As a member of the Caris POA, UNM Comprehensive Cancer Center researchers and clinicians will have opportunities to collaborate with other leading institutions across the network on investigator-initiated studies, translational research programs, biomarker discovery efforts and publications designed to advance the understanding and treatment of cancer. The alliance has contributed to more than 800 investigator-initiated publications since its inception and continues to drive innovation through large-scale molecular and clinical data analysis.
“The University of New Mexico Comprehensive Cancer Center is dedicated to delivering cutting-edge cancer care and advancing research that benefits the patients and communities we serve,” said Bernard Tawfik, MD, an associate professor at UNM and the medical director of the UNM Comprehensive Cancer Center Clinical Research Office. “Joining the Caris Precision Oncology Alliance provides a valuable opportunity for research to help our patients, advance science to treat cancer, and collaborate with leading cancer experts nationwide to help shape the future of precision oncology.”
The Caris Precision Oncology Alliance is one of the largest and most active precision oncology networks in the world. Through collaboration among member institutions, the alliance seeks to accelerate scientific discovery, validate novel molecular signatures, support clinical trials and enable new approaches to personalized treatment strategies.
